Enlivex (ENLV) has released an update.
Enlivex Therapeutics Ltd. has reported a notable decrease in their total assets, from $36.831 million at the end of December 2023 to $31.047 million by March 2024. The company faced a comprehensive loss of $4.140 million for the first quarter of 2024, improving from a loss of $7.218 million in the same period the previous year. Shareholders’ equity also saw a reduction, from $30.084 million to $26.851 million, reflecting the company’s ongoing financial challenges.
For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.
